Prototype foamy virus bet impairs the dimerization and cytosolic solubility of human APOBEC3G

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 9030-9040

  Jaguva Vasudevan, Ananda Ayyappan ^a   Mario Perkovic ^a,b,d   Bulliard, Yannick ^c,e   Cichutek, Klaus ^b   Trono, Didier ^c   Häussinger, Dieter ^a   Münk, Carsten ^a  

^a Department of Orthopedic Surgery   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c EPFL   (Switzerland)

^d GOETHE UNIVERSITY   (Germany)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; PROTEIN BET; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL FRACTIONATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOSOL; DIMERIZATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIMIAN IMMUNODEFICIENCY VIRUS; SOLUBILITY; SPUMA VIRUS; VIRION;

CELL LINE; CYTIDINE DEAMINASE; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN MULTIMERIZATION; RETROVIRIDAE PROTEINS; SIMIAN FOAMY VIRUS; SOLUBILITY; VIRULENCE FACTORS;

EID: 84881218219     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03385-12     Document Type: Article

References (59)

1. LaRue RS, Jonsson SR, Silverstein KA, Lajoie M, Bertrand D, ElMabrouk N, Hotzel I, Andresdottir V, Smith TP, Harris RS. 2008. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9:104. doi:10.1186/1471-2199-9-104.
2. Münk C, Willemsen A, Bravo IG. 2012. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol. Biol. 12:71. doi:10.1186/1471-2148-12-71.
3. Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C. 2012. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3 induced mutagenesis through its Vif protein. Viruses 4:3132-3161.
4. Sheehy AM, Erthal J. 2012. APOBEC3 versus retroviruses, immunity versus invasion: clash of the titans. Mol. Biol. Int. 2012:974924. doi:10 .1155/2012/974924.
5. Chiu YL, Greene WC. 2009. APOBEC3G: an intracellular centurion. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:689-703.
6. Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K. 2007. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 369:329-339.
7. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27. doi:10.1186/1742-4690-1-27.
8. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K. 2007. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81:8236-8246.
9. Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J. 2005. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280:8765-8775.
10. Britan-Rosich E, Nowarski R, Kotler M. 2011. Multifaceted counterAPOBEC3G mechanisms employed by HIV-1 Vif. J. Mol. Biol. 410:1065-1076.
11. Arias JF, Koyama T, Kinomoto M, Tokunaga K. 2012. Retroelements versus APOBEC3 family members: no great escape from the magnificent seven. Front. Microbiol. 3:275. doi:10.3389/fmicb.2012.00275.
12. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. 2007. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. Sci. U. S. A. 104:2915-2920.
13. Ooms M, Krikoni A, Kress AK, Simon V, Münk C. 2012. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human Tlymphotropic virus type 1. J. Virol. 86:6097-6108.
14. Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, Portis JL, Hasenkrug KJ, Evans LH. 2010. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J. Virol. 84:10933-10936.
15. Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, Rein AR, Fan H, Ross SR. 2013. Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc. Natl. Acad. Sci. U. S. A. 110:9078-9083.
16. Chareza S, Slavkovic LD, Liu Y, Rathe AM, Münk C, Zabogli E, Pistello M, Löchelt M. 2012. Molecular and functional interactions of cat APOBEC3 and feline foamy and immunodeficiency virus proteins: different ways to counteract host-encoded restriction. Virology 424:138-146.
17. Löchelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rosler U, Battenberg M, Saib A, Flory E, Cichutek K, Münk C. 2005. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. U. S. A. 102:7982-7987.
18. Münk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O'Brien SJ, Löchelt M, Yuhki N. 2008. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 9:R48. doi:10.1186/gb-2008-9-3-r48.
19. Perkovic M, Schmidt S, Marino D, Russell RA, Stauch B, Hofmann H, Kopietz F, Kloke BP, Zielonka J, Strover H, Hermle J, Lindemann D, Pathak VK, Schneider G, Löchelt M, Cichutek K, Münk C. 2009. Species-specific inhibition of APOBEC3C by the prototype foamy virus protein Bet. J. Biol. Chem. 284:5819-5826.
20. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR. 2005. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J. Virol. 79: 8724-8731.
21. Liu W, Worobey M, Li Y, Keele BF, Bibollet-Ruche F, Guo Y, Goepfert PA, Santiago ML, Ndjango JB, Neel C, Clifford SL, Sanz C, Kamenya S, Wilson ML, Pusey AE, Gross-Camp N, Boesch C, Smith V, Zamma K, Huffman MA, Mitani JC, Watts DP, Peeters M, Shaw GM, Switzer WM, Sharp PM, Hahn BH. 2008. Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees. PLoS Pathog. 4:e1000097. doi:10.1371/journal.ppat.1000097.
22. Herchenroder O, Renne R, Loncar D, Cobb EK, Murthy KK, Schneider J, Mergia A, Luciw PA. 1994. Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). Virology 201:187-199.
23. Locatelli S, Peeters M. 2012. Cross-species transmission of simian retroviruses: how and why they could lead to the emergence of new diseases in the human population. AIDS 26:659-673.
24. Sandstrom PA, Phan KO, Switzer WM, Fredeking T, Chapman L, Heneine W, Folks TM. 2000. Simian foamy virus infection among zoo keepers. Lancet 355:551-552.
25. Switzer WM, Bhullar V, Shanmugam V, Cong ME, Parekh B, Lerche NW, Yee JL, Ely JJ, Boneva R, Chapman LE, Folks TM, Heneine W. 2004. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J. Virol. 78:2780-2789.
26. Heneine W, Schweizer M, Sandstrom P, Folks T. 2003. Human infection with foamy viruses. Curr. Top. Microbiol. Immunol. 277:181-196.
27. Khan AS. 2009. Simian foamy virus infection in humans: prevalence and management. Expert Rev. Anti Infect. Ther. 7:569-580.
28. Linial M. 2000. Why aren't foamy viruses pathogenic? Trends Microbiol. 8:284-289.
29. Bock M, Heinkelein M, Lindemann D, Rethwilm A. 1998. Cells expressing the human foamy virus (HFV) accessory Bet protein are resistant to productive HFV superinfection. Virology 250:194-204.
30. Meiering CD, Linial ML. 2002. Reactivation of a complex retrovirus is controlled by a molecular switch and is inhibited by a viral protein. Proc. Natl. Acad. Sci. U. S. A. 99:15130-15135.
31. Delebecque F, Suspene R, Calattini S, Casartelli N, Saib A, Froment A, Wain-Hobson S, Gessain A, Vartanian JP, Schwartz O. 2006. Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 80:605-614.
32. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
33. Duda A, Stange A, Luftenegger D, Stanke N, Westphal D, Pietschmann T, Eastman SW, Linial ML, Rethwilm A, Lindemann D. 2004. Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity. J. Virol. 78:13865-13870.
34. Pietschmann T, Heinkelein M, Heldmann M, Zentgraf H, Rethwilm A, Lindemann D. 1999. Foamy virus capsids require the cognate envelope protein for particle export. J. Virol. 73:2613-2621.
35. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403.
36. Bulliard Y, Turelli P, Rohrig UF, Zoete V, Mangeat B, Michielin O, Trono D. 2009. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83:12611-12621.
37. Achong BG, Mansell PW, Epstein MA, Clifford P. 1971. An unusual virus in cultures from a human nasopharyngeal carcinoma. J. Natl. Cancer Inst. 46:299-307.
38. Cullen BR. 1986. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973-982.
39. Muckenfuss H, Kaiser JK, Krebil E, Battenberg M, Schwer C, Cichutek K, Münk C, Flory E. 2007. Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res. 35:3784-3796.
40. Fang L, Landau NR. 2007. Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay. Virology 359:162-169.
41. Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR. 2004. Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319:343-352.
42. Moosmann P, Rusconi S. 1996. Alpha complementation of LacZ in mammalian cells. Nucleic Acids Res. 24:1171-1172.
43. Löchelt M, Zentgraf H, Flugel RM. 1991. Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel1 gene. Virology 184:43-54.
44. Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ. 1995. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J. Virol. 69:4582-4586.
45. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M. 2008. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 15:1059-1066.
46. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. doi:10.1371/journal.ppat .1000330.
47. Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.
48. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, Sen U, Stevens RC, Goodman MF, Chen XS. 2008. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456:121-124.
49. Soros VB, Yonemoto W, Greene WC. 2007. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3:e15. doi:10.1371 /journal.ppat.0030015.
50. Kreisberg JF, Yonemoto W, Greene WC. 2006. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203:865-870.
51. Ramsby M, Makowski G. 2011. Differential detergent fractionation of eukaryotic cells. Cold Spring Harb. Protoc. 2011:prot5592. doi:10.1101 /pdb.prot5592.
52. Ramsby ML, Makowski GS. 1999. Differential detergent fractionation of eukaryotic cells. Analysis by two-dimensional gel electrophoresis. Methods Mol. Biol. 112:53-66.
53. Khan MA, Goila-Gaur R, Kao S, Miyagi E, Walker RC, Jr, Strebel K. 2009. Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 6:99. doi:10.1186/1742-4690-6-99.
54. Huthoff H, Malim MH. 2007. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81:3807-3815.
55. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
56. Stanley DJ, Bartholomeeusen K, Crosby DC, Kim DY, Kwon E, Yen L, Cartozo NC, Li M, Jager S, Mason-Herr J, Hayashi F, Yokoyama S, Krogan NJ, Harris RS, Peterlin BM, Gross JD. 2012. Inhibition of a NEDD8 cascade restores restriction of HIV by APOBEC3G. PLoS Pathog. 8:e1003085. doi:10.1371/journal.ppat.1003085.
57. Han GZ, Worobey M. 2012. An endogenous foamy virus in the aye-aye (Daubentonia madagascariensis). J. Virol. 86:7696-7698.
58. Han GZ, Worobey M. 2012. An endogenous foamy-like viral element in the coelacanth genome. PLoS Pathog. 8:e1002790. doi:10.1371/journal .ppat.1002790.
59. Katzourakis A, Gifford RJ, Tristem M, Gilbert MT, Pybus OG. 2009. Macroevolution of complex retroviruses. Science 325:1512. doi:10.1126 /science.1174149.